Home/Pipeline/INGREZZA

INGREZZA

Tourette Syndrome

Phase 3Active

Key Facts

Indication

Tourette Syndrome

Phase

Phase 3

Status

Active

Company

Neurocrine Biosciences

About Neurocrine Biosciences

Founded in 1992, Neurocrine Biosciences has evolved from a research-focused biotech into a successful commercial company with over $1.5 billion in annual revenue. Their expertise in neuroscience drug development has produced breakthrough treatments like INGREZZA for tardive dyskinesia and a promising pipeline including programs for Parkinson's disease, schizophrenia, and endometriosis. The company combines strong commercial execution with continued innovation in CNS therapeutics.

View full company profile

Therapeutic Areas

Neurology Psychiatry Movement Disorders Endocrinology Women's Health

Other Tourette Syndrome Drugs

Drug	Company	Phase	Status
Sepranolone	Relmada Therapeutics	Proof-of-Concept	Positive proof-of-concept data reported.